Is the JAK2^V617F mutation detectable in healthy volunteers?MARTINAUD, Christophe; BRISOU, Patrick; MOZZICONACCI, Marie-Joelle et al.American journal of hematology. 2010, Vol 85, Num 4, pp 287-288, issn 0361-8609, 2 p.Article

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneGODFREY, Anna L; CHEN, Edwin; BIJOU, Fontanet et al.Blood. 2012, Vol 120, Num 13, pp 2704-2707, issn 0006-4971, 4 p.Article

PLA2R1 Mediates Tumor Suppression by Activating JAK2VINDRIEUX, David; AUGERT, Arnaud; DE LAUNOIT, Yvan et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 20, pp 6334-6345, issn 0008-5472, 12 p.Article

The cell cycle regulator CDC25A is a target for JAK2^V617F oncogeneGAUTIER, Emilie-Fleur; PICARD, Muriel; DUCOMMUN, Bernard et al.Blood. 2012, Vol 119, Num 5, pp 1190-1199, issn 0006-4971, 10 p.Article

Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasmPEYRO-SAINT-PAUL, Hélène; HERMITTE, Fabienne.Blood. 2010, Vol 116, Num 11, pp 1994-1995, issn 0006-4971, 2 p.Article

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitorLUCET, Isabelle S; FANTINO, Emmanuelle; ROSSJOHN, Jamie et al.Blood. 2006, Vol 107, Num 1, pp 176-183, issn 0006-4971, 8 p.Article

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasmsBERNARD, L; BELISLE, C; MOLLICA, L et al.Leukemia. 2009, Vol 23, Num 2, pp 287-291, issn 0887-6924, 5 p.Article

Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negativeRANDI, Maria Luigia; PUTTI, Maria Caterina; SCAPIN, Margherita et al.Blood. 2006, Vol 108, Num 10, pp 3600-3602, issn 0006-4971, 3 p.Article

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617FBERKOFSKY-FESSLER, Windy; BUZZAI, Monica; WEIJIA ZHANG et al.Clinical cancer research (Print). 2010, Vol 16, Num 17, pp 4339-4352, issn 1078-0432, 14 p.Article

JAK2^V617F : prevalence in a large Chinese hospital population. CommentaryPARDANANI, Animesh; XUESONG XU; QI ZHANG et al.Blood. 2007, Vol 109, Num 1, issn 0006-4971, 8,339-342 [5 p.]Article

Characterization of murine JAK2^V617F-positive myeloproliferative diseaseBUMM, Thomas G. P; ELSEA, Collin; CORBIN, Amie S et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11156-11165, issn 0008-5472, 10 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria : PIH: Molecular mechanism, diagnosis, and treatment for myeloproliferative neoplasmsWADLEIGH, Martha; TEFFERI, Ayalew.International journal of hematology. 2010, Vol 91, Num 2, pp 174-179, issn 0925-5710, 6 p.Article

Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopeniaFABRIS, Fabrizio; SCANDELLARI, Raffaella; VETTORE, Silvia et al.Thrombosis and haemostasis. 2010, Vol 104, Num 4, pp 858-859, issn 0340-6245, 2 p.Article

Myeloproliferative neoplasm induced by constitutive expression of JAK2^V617F in knock-in miceMARTY, Caroline; LACOUT, Catherine; MARTIN, Antoine et al.Blood. 2010, Vol 116, Num 5, pp 783-787, issn 0006-4971, 5 p.Article

Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1NILSSON, Jeanette; HELOU, Khalil; KOVACS, Anikó et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 5, pp 2020-2029, issn 0008-5472, 10 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

On the molecular origins of the chronic myeloproliferative disorders : it all makes senseKAUSHANSKY, Kenneth.Blood. 2005, Vol 105, Num 11, pp 4187-4190, issn 0006-4971, 4 p.Article

Decrease in JAK2^V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraKURIAKOSE, Emil; VANDRIS, Katherine; LYNN WANG, Y et al.Haematologica (Roma). 2012, Vol 97, Num 4, pp 538-542, issn 0390-6078, 5 p.Article

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FTEFFERI, A; JIMMA, T; SULAI, N. H et al.Leukemia. 2012, Vol 26, Num 3, pp 475-480, issn 0887-6924, 6 p.Article

Bone Marrow Stroma-Secreted Cytokines Protect JAK2^V617F-Mutated Cells from the Effects of a JAK2 InhibitorMANSHOURI, Taghi; ESTROV, Zeev; VERSTOVSEK, Srdan et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 11, pp 3831-3840, issn 0008-5472, 10 p.Article

Extent of hematopoietic involvement by TET2 mutations in JAK2^V617F polycythemia veraSWIERCZEK, Sabina I; YOON, Donghoon; BELLANNE-CHANTELOT, Christine et al.Haematologica (Roma). 2011, Vol 96, Num 5, pp 775-778, issn 0390-6078, 4 p.Article

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigenBETTS, Brian C; ABDEL-WAHAB, Omar; CURRAN, Shane A et al.Blood. 2011, Vol 118, Num 19, pp 5330-5339, issn 0006-4971, 10 p.Article

The JAK2 exon 12 mutations: A comprehensive reviewSCOTT, Linda M.American journal of hematology. 2011, Vol 86, Num 8, pp 668-676, issn 0361-8609, 9 p.Article

The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemiaNAHAJEVSZKY, Sarolta; ANDRIKOVICS, Hajnalka; LUEFF, Sandor et al.Haematologica (Roma). 2011, Vol 96, Num 11, pp 1613-1618, issn 0390-6078, 6 p.Article